Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 5, 2010, Pages 445-449

  Speich, Rudolf ^a   Schneider, Silvia ^a   Hofer, Markus ^a   Irani, Sarosh ^a   Vogt, Peter ^a   Weder, Walter ^a   Boehler, Annette ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute rejection episode (AR); Azathioprine (AZA); Bronchiolitis obliterans syndrome (BOS); Bronchoalveolar lavage (BAL); Mycophenolate mofetil (MMF); Transbronchial lung biopsy (TBB)

Indexed keywords

AZATHIOPRINE; HEMOSIDERIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; EOSINOPHIL COUNT; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; LUNG BIOPSY; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LUNG TRANSPLANTATION; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; TREATMENT OUTCOME;

EID: 77955422085     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.04.004     Document Type: Article

References (34)

1. Estenne M., Maurer J.R., Boehler A., Egan J.J., Frost A., Hertz M., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002, 21:297-310.
2. Estenne M., Hertz M.I. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002, 166:440-444.
3. Boehler A., Kesten S., Weder W., Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest 1998, 114:1411-1426.
4. McKane B.W., Trulock E.P., Patterson G.A., Mohanakumar T. Lung transplantation and bronchiolitis obliterans: an evolution in understanding. Immunol Res 2001, 24:177-190.
5. Scott J.P., Higenbottam T.W., Sharples L., Clelland C.A., Smyth R.L., Stewart S., et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 1991, 51:813-817.
6. Bando K., Paradis I.L., Similo S., Konishi H., Komatsu K., Zullo T.G., et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995, 110:4-13.
7. Girgis R.E., Tu I., Berry G.J., Reichenspurner H., Valentine V.G., Conte J.V., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996, 15:1200-1208.
8. Heng D., Sharples L.D., McNeil K., Stewart S., Wreghitt T., Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998, 17:1255-1263.
9. European Mycophenolate Mofetil Cooperative Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995, 345:1321-1325.
10. Mathew T.H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998, 65:1450-1454.
11. Kobashigawa J., Miller L., Renlund D., Mentzer R., Alderman E., Bourge R., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 1998, 66:507-515.
12. Eisen H.J., Kobashigawa J., Keogh A., Bourge R., Renlund D., Mentzer R., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005, 24:517-525.
13. O'Hair D.P., Cantu E., McGregor C., Jorgensen B., Gerow-Smith R., Galantowicz M.E., et al. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant 1998, 17:864-868.
14. Ross D.J., Waters P.F., Levine M., Kramer M., Ruzevich S., Kass R.M. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 1998, 17:768-774.
15. Zuckermann A., Klepetko W., Birsan T., Taghavi S., Artemiou O., Wisser W., et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999, 18:432-440.
16. Whyte R.I., Rossi S.J., Mulligan M.S., Florn R., Baker L., Gupta S., et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 1997, 64:945-948.
17. Speich R., Boehler A., Thurnheer R., Weder W. Salvage therapy with Mycophenolate mofetil for lung transplant bronchiolitis obliterans. Importance of dosage. Transplantation 1997, 64:533-535.
18. McNeil K., Glanville A.R., Wahlers T., Knoop C., Speich R., Mamelok R.D., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006, 81:998-1003.
19. Palmer S.M., Baz M.A., Sanders L., Miralles A.P., Lawrence C.M., Rea J.B., et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001, 71:1772-1776.
20. Trulock E.P., Ettinger N.A., Brunt E.M., Pasque M.K., Kaiser L.R., Cooper J.D. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992, 102:1049-1054.
21. Boehler A., Vogt P., Zollinger A., Weder W., Speich R. Prospective study of the value of transbronchial lung biopsy after lung transplantation. Eur Respir J 1996, 9:658-662.
22. Swanson S.J., Mentzer S.J., Reilly J.J., Bueno R., Lukanich J.M., Jaklitsch M.T., et al. Surveillance transbronchial lung biopsies: implication for survival after lung transplantation. J Thorac Cardiovasc Surg 2000, 119:27-37.
23. Speich R., Boehler A., Zalunardo M., Stocker R., Russi E.W., Weder W. Improved results after lung transplantation - analysis of factors. Swiss Med Wkly 2001, 131:238-245.
24. Sandmeier P., Speich R., Grebski E., Vogt P., Russi E.W., Weder W., et al. Iron accumulation in lung allografts is associated with acute rejection but not with adverse outcome. Chest 2005, 128:1379-1384.
25. Yousem S.A., Berry G.J., Cagle P.T., Chamberlain D., Husain A.N., Hruban R.H., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996, 15:1-15.
26. Venuta F., Boehler A., Rendina E.A., De Giacomo T., Speich R., Schmid R., et al. Complications in the native lung after single lung transplantation. Eur J Cardiothorac Surg 1999, 16:54-58.
27. Bewig B., Stewart S., Bottcher H., Bastian A., Tiroke A., Hirt S., et al. Eosinophilic alveolitis in BAL after lung transplantation. Transpl Int 1999, 12:266-272.
28. Tikkanen J., Lemstrom K., Halme M., Pakkala S., Taskinen E., Koskinen P. Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart-lung allograft recipients. Clin Transplant 2001, 15:77-88.
29. Scholma J., Slebos D.J., Boezen H.M., van den Berg J.W., van der Bij W., de Boer W.J., et al. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2000, 162:2221-2225.
30. Ward C., Whitford H., Snell G., Bao H., Zheng L., Reid D., et al. Bronchoalveolar lavage macrophage and lymphocyte phenotypes in lung transplant recipients. J Heart Lung Transplant 2001, 20:1064-1074.
31. Henke J.A., Golden J.A., Yelin E.H., Keith F.A., Blanc P.D. Persistent increases of BAL neutrophils as a predictor of mortality following lung transplant. Chest 1999, 115:403-409.
32. Richter M.H., Zahn S., Kraus M., Mohr F.W., Olbrich H.G. Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model: comparative study with cyclosporine and FK 506. J Heart Lung Transplant 2003, 22:1107-1116.
33. Farivar A.S., MacKinnon-Patterson B., Barnes A.D., Mulligan M.S. The effect of anti-inflammatory properties of mycophenolate mofetil on the development of lung reperfusion injury. J Heart Lung Transplant 2005, 24:2235-2242.
34. Samiento J.M., Dockrell D.H., Schwab T.R., Munn S.R., Paya C.V. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000, 14:136-138.